Aggressive systemic mastocytosis: midostaurin is safe, feasible and associated with durable response post-haploidentical allogeneic stem cell transplant

Br J Haematol. 2019 Sep;186(5):e139-e141. doi: 10.1111/bjh.15980. Epub 2019 May 21.

¹ Department of Medicine, University of Southern California, Keck School of Medicine of USC, Los Angeles, CA, USA.
² Department of Pathology, University of California Irvine, Children Hospital of Orange County, Los Angeles, CA, USA.
³ Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Keck School of Medicine of USC, USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
⁴ Pulmonary, Critical Care, University of Southern California, Keck School of Medicine of USC, Los Angeles, CA, USA.

No abstract available

Keywords: aggressive systemic mastocytosis; haploidentical haematopoietic stem cell transplant; midostaurin.

Publication types